Benefit design and specialty drug use

Area of Science:

• Health economics
• Pharmaceutical policy
• Patient financial risk

Background:

• Privately insured patients with chronic conditions like cancer, kidney disease, rheumatoid arthritis, and multiple sclerosis often require expensive specialty drugs.
• Employer-sponsored health insurance does not always shield these patients from significant out-of-pocket healthcare expenditures.
• The cost-effectiveness and accessibility of specialty drugs remain critical concerns in healthcare management.

Purpose of the Study:

• To analyze patient spending on specialty drugs for four specific chronic conditions.
• To evaluate the impact of cost-sharing on the utilization of specialty drugs.
• To inform healthcare policy regarding coverage and management of high-cost specialty medications.

Main Methods:

• Examination of healthcare spending data for privately insured patients.
• Analysis of patient out-of-pocket expenses for cancer, kidney disease, rheumatoid arthritis, and multiple sclerosis treatments.
• Calculation of price elasticities to determine cost sensitivity of specialty drug use.

Main Results:

• Specialty drug utilization demonstrated low price elasticity, ranging from 0.01 to 0.21, indicating insensitivity to cost-sharing.
• Patients with these conditions, even with insurance, are at substantial risk for high out-of-pocket spending.
• Cost-sharing appears to be an ineffective mechanism for controlling specialty drug use.

Conclusions:

• Care management strategies should prioritize ensuring that patients who will gain the most benefit from specialty drugs receive them.
• Limiting coverage for specialty drugs, once patient benefit is established, is economically inefficient.
• Policy considerations should focus on value-based access rather than restrictive cost-sharing for essential specialty medications.